Martina Hrabinova

Dr. Martina Hrabinova

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MIroslav PohankaMIroslav Pohanka
MIroslav Pohanka
MHMartina Hrabinova
Martina Hrabinova
Kamil KucaKamil Kuca
Kamil Kuca
JSJean-Pierre Simonato
Jean-Pierre Simonato
Assay of acetylcholinesterase (AChE) activity plays an important role in diagnostic, detection of pesticides and nerve agents, in vitro characterization of toxins and drugs including potential treatments for Alzheimer’s disease. These experiments were done in order to determine whether indoxylacetate could be an adequate chromogenic reactant for AChE assay evaluation. Moreover, the results were compared to the standard Ellman’s method. We calculated Michaelis constant Km (2.06 × 10−4 mol/L for acetylthiocholine and 3.21 × 10−3 mol/L for indoxylacetate) maximum reaction velocity Vmax (4.97 × 10−7 kat for acetylcholine and 7.71 × 10−8 kat for indoxylacetate) for electric eel AChE. In a second part, inhibition values were plotted for paraoxon, and reactivation efficacy was measured for some standard oxime reactivators: obidoxime, pralidoxime (2-PAM) and HI-6. Though indoxylacetate is split with lower turnover rate, this compound appears as a very attractive reactant since it does not show any chemical reactivity with oxime antidots and thiol used for the Ellman’s method. Thus it can be advantageously used for accurate measurement of AChE activity. Suitability of assay for butyrylcholinesterase activity assessment is also discussed.

10 November 2015 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Eugenie  NepovimovaEugenie Nepovimova
Eugenie Nepovimova
Jan KorabecnyJan Korabecny
Jan Korabecny
RDRafael Doležal
Rafael Doležal
KBKaterina Babkova
Katerina Babkova
AOAles Ondrejicek
Ales Ondrejicek
Kamil KucaKamil Kuca
Kamil Kuca

12 August 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SHSlavka Hamulakova
Slavka Hamulakova
LJLadislav Janovec
Ladislav Janovec
MHMartina Hrabinova
Martina Hrabinova
KSKatarina Spilovska
Katarina Spilovska
Jan KorabecnyJan Korabecny
Jan Korabecny
JIJan Imrich
Jan Imrich

1 February 2017 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JJJakub Jeřábek
Jakub Jeřábek
EUElisa Uliassi
Elisa Uliassi
LGLaura Guidotti
Laura Guidotti
Jan KorabecnyJan Korabecny
Jan Korabecny
OSOndřej Soukup
Ondřej Soukup
MBMaria Laura Bolognesi
Maria Laura Bolognesi

1 August 2016 in Journal of Inorganic Biochemistry
Verified
Journal Article
Closed access
SHSlavka Hamulakova
Slavka Hamulakova
PPPatrik Poprac
Patrik Poprac
KJKlaudia Jomova
Klaudia Jomova
VBVlasta Brezova
Vlasta Brezova
PLPeter Lauro
Peter Lauro
Marian ValkoMarian Valko
Marian Valko

24 August 2023 in Archives of Toxicology
Verified
Journal Article
Open access
PDF file
JOJakub Opravil
Jakub Opravil
JPJaroslav Pejchal
Jaroslav Pejchal
VFVladimir Finger
Vladimir Finger
Jan KorabecnyJan Korabecny
Jan Korabecny
TRTomas Rozsypal
Tomas Rozsypal
DJDaniel Jun
Daniel Jun
“Novichok” refers to a new group of nerve agents called the A-series agents. Their existence came to light in 2018 after incidents in the UK and again in 2020 in Russia. They are unique organophosphorus-based compounds developed during the Cold War in a program called Foliant in the USSR. This review is based on original chemical entities from Mirzayanov's memoirs published in 2008. Due to classified research, a considerable debate arose about their structures, and hence, various structural moieties were speculated. For this reason, the scientific literature is highly incomplete and, in some cases, contradictory. This review critically assesses the information published to date on this class of compounds. The scope of this work is to summarize all the available and relevant information, including the physicochemical properties, chemical synthesis, mechanism of action, toxicity, pharmacokinetics, and medical countermeasures used to date. The environmental stability of A-series agents, the lack of environmentally safe decontamination, their high toxicity, and the scarcity of information on post-contamination treatment pose a challenge for managing possible incidents.